We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Rebuffs Reimbursement for Roche’s Combination Therapy for Melanoma
NICE Rebuffs Reimbursement for Roche’s Combination Therapy for Melanoma
The UK’s price watchdog recommended against the reimbursement of Roche’s Cotellic and Zelboraf for the treatment of BRAF V600 mutation-positive melanoma, citing the expensive list price for the products.